SCHEMBL12409306

SCHEMBL12409306

NS(=O)(=O)c1ccc(CNc2nccn3c(-c4cccc(F)c4)cnc23)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 1/20 0.49
NTRK1 P04629 3/20 0.48
NTRK3 Q16288 1/20 0.48
NTRK2 Q16620 1/20 0.48
ADORA3 P0DMS8 4/20 0.47
TTK P33981 4/20 0.46
MAPT P10636 3/20 0.42
KDM4E B2RXH2 2/20 0.42
PTGS2 P35354 1/20 0.42
PI4KB Q9UBF8 1/20 0.42
MEN1 O00255 1/20 0.42
ALDH1A1 P00352 1/20 0.42
GLA P06280 1/20 0.42
GAA P10253 1/20 0.42
HPGD P15428 1/20 0.42
KMT2A Q03164 1/20 0.42
ZAP70 P43403 1/20 0.41
TP53 P04637 2/20 0.40
POLB P06746 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12409304 0.89 TTK (0.48) SYKNTRK1NTRK3NTRK2ADORA3
SCHEMBL12409231 0.88 TTK (0.51) SYKNTRK1NTRK3NTRK2TTK
SCHEMBL12409310 0.88 TTK (0.57) ADORA3TTKMAPTKDM4EZAP70
SCHEMBL12409313 0.88 TTK (0.49) NTRK1NTRK3NTRK2ADORA3TTK
SCHEMBL12409251 0.86 ZAP70 (0.50) ADORA3TTKMAPTKDM4EPTGS2
SCHEMBL12409257 0.86 PI4KB (0.53) NTRK1NTRK3NTRK2ADORA3TTK
SCHEMBL12409293 0.85 CYP1A2 (0.47) TTKMAPTKDM4EPI4KBMEN1
SCHEMBL12409245 0.85 TTK (0.49) NTRK1TTKPI4KBZAP70
SCHEMBL12409248 0.85 ADORA3 (0.49) NTRK1ADORA3TTKPTGS2PI4KB
SCHEMBL12490118 0.85 TTK (0.45) NTRK1NTRK3NTRK2ADORA3TTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8362018-B2 Substituted imidazo[1,2-a]pyrazine compounds useful for the treatment of viral infections BIOFOCUS DPI, LTD. (GB) 2013-01-29 US disclosed
US-8362018-B2 Substituted imidazo[1,2-a]pyrazine compounds useful for the treatment of viral infections BIOFOCUS DPI, LTD. (GB) 2013-01-29 US disclosed
US-20110166147-A1 IMIDAZOPYRAZINE COMPOUNDS BIOFOCUS DPI, LTD. (GB) 2011-07-07 US disclosed
US-20110166147-A1 IMIDAZOPYRAZINE COMPOUNDS BIOFOCUS DPI, LTD. (GB) 2011-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166147-A1 IMIDAZOPYRAZINE COMPOUNDS CYP3A5, HAVCR2, CYP3A43 SYK 2240/4885NTRK1 3339/4885NTRK3 2491/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.